Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up
2025 ASCO Annual Meeting
Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Abstract 5005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So in 2025, the standard of care for men who have metastatic hormone-sensitive prostate cancer is treatment intensification, either with doublet therapy, that means androgen deprivation therapy plus an androgen receptor pathway inhibitor, or triplet therapy with that doublet plus docetaxel. And that's based on data like the ARCHES trial that I'm presenting at ASCO 2025. In 2019, we published in the Journal of Clinical Oncology that enzalutamide plus ADT in the ARCHES trial delayed progression-free survival by over 60%. That led to the FDA approval of the enzalutamide ADT regimen based on the ARCHES trial of over 1,150 patients. This is a randomized global trial, the primary endpoint of which was radiographic progression-free survival. In 2021 we updated the data that shows that that delay in progression-free survival translated into an overall survival improvement by about 30%. So this was a remarkable finding in 2021. In 2025 we're updating the data where the minimum follow-up for all patients is now five years. So we're asking the question what does this long-term survival look like for our patients and this is applicable to clinical practice as we're now treating patients, as I mentioned, in 2025 with treatment intensification routinely. And the question is what happens to these men long-term. The great news from the ARCHES long-term survival follow-up is that men are living longer, a 30% extension of survival. That means at five years 13% more men are alive at that important landmark. This ranges across different subgroups by disease volume, disease risk, geography, age, prior chemotherapy, but the absolute improvement ranges from about 9 to 17%. One of the more remarkable findings was the median survival improvement in high-volume disease patients. Survival improved from four years to about seven years. That's three extra years of life where these men can enjoy time with their family, delay progression and the symptomatology that that causes, delay the need for chemotherapy and subsequent therapy, which have additional toxicities. Now with this improved efficacy and delaying progression and living longer comes the need for close attention to survivorship. There are enhanced toxicities with all of the androgen receptor pathway inhibitors. With enzalutamide we do see increases in fatigue, falls, some fractures, particularly in older men. We see neurocognitive effects in a few percent of patients. Radioligand therapy, EZH2 inhibitors, you know, ways to further build on this and extend the lives of our patients.
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501).
The ASCO Post Staff
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501).
The ASCO Post Staff
Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, IRCCS, University of Milano, discusses patient-reported outcomes from the phase III EMBER-3 trial, which investigated treatment with imlunestrant, investigator’s choice of standard endocrine therapy, or imlunestrant plus abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer (Abstract 1001).
The ASCO Post Staff
Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, discusses data from the TIGOS trial, a phase III study comparing the first-line use of atigotatug (an antifucosyl-GM1 monoclonal antibody) plus nivolumab fixed-dose combination with chemotherapy vs atezolizumab with chemotherapy in patients with extensive-stage small cell lung cancer (SCLC) (Abstract TPS8127).
The ASCO Post Staff
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract 5014).